Effects of Compression in Mixed Ulcers
ULCEREMIXTE
1 other identifier
observational
25
1 country
1
Brief Summary
About 15% to 30% of patients with venous leg ulcers have a peripheral arterial disease (PAD) associated. The compression band is still a controversial issue in this context. It allows the reduction of venous hypertension and edema, but it could potentially degrade the arterial infusion of high levels of compression. The French High Authority for Health (HAS) defines mixed ulcers by IPS between 0.5 and 0.9. Investigators distinguish mixed ulcers blood predominance for IPS between 0.5 and 0.7; and mixed ulcers predominantly venous blood with moderate involvement for IPS values between 0.7 and 0.9. Several studies have shown that IPS\> 0.8 allowed a high compression, between 30 and 40 mmHg. In the case of mixed ulcers with IPS between 0.6 and 0.8, the HAS recommends using a lighter compression, bit by elastic bands (exercising low power compression at rest) under medical supervision, informing the patient to remove the bandage if pain or aggravation. It is therefore necessary to adapt the compression therapy in case of venous ulcers associated with arterial disease by providing a lower compression 30 mmHg short stretch. For HAS, IPS \<0.6 against indicates compression. A recent study showed that compression bit elastic bands could not only improve venous return, but it would also increase the distal arterial flow in a patient population with mixed ulcers. In this study, 25 patients had between IPS 0.5 and 0.8; or for certain patients below the threshold of 0.6 indicates that against a compression according to HAS. To our knowledge this is the only study that has examined the effect of compression on blood perfusion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 13, 2016
CompletedFirst Posted
Study publicly available on registry
July 20, 2016
CompletedJuly 27, 2016
July 1, 2016
10 months
July 13, 2016
July 26, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment of change of pain numeric scale
Day 1, just before the exam, 10minutes after the exam and 24 hours after the exam
Secondary Outcomes (4)
Assessment of change of distal arterial pressures of the compression carrier leg
Day 1, just before the exam, 10minutes after the exam and 24 hours after the exam
Assessment of change of IPS (systolic pressure index) ankle pressures
Day 1, just before the exam, 10minutes after the exam and 24 hours after the exam
Assessment of change of pressure exerted by low elastic bandage
Day 1, just before the exam, 10minutes after the exam and 24 hours after the exam
Assessment of IPS (systolic pressure index) arm pressures
Day 1, just before the exam, 10minutes after the exam and 24 hours after the exam
Interventions
Eligibility Criteria
Subjects older than 18 years, suffering from an ulcer of mixed origin leg, and followed in the vascular medicine department of St. Joseph Hospital Group Paris.
You may qualify if:
- A IPS 0.5 and 0.9, with a systolic pressure at the ankle\> 70 mmHg
- A big toe pressure index (IPGO) \<0.7, with a systolic pressure of the big toe (PGO)\> 50 mmHg
You may not qualify if:
- Topics aged under 18,
- A normal IPS that is to say between 0.9 and 1.3, a critical ischemia (defined as ankle pressure \<70 mmHg and / or systolic pressure of the big toe \<50 mmHg)
- Presence of peripheral neuropathy,
- Presence of heart failure,
- Refusal to participate in the study or to sign the consent,
- Impaired cognitive function not to participate in a clinical study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Groupe Hospitalier Paris Saint Joseph
Paris, Île-de-France Region, 75014, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
STANSAL Audrey, MD
Groupe Hospitalier Paris Saint-Joseph (FRANCE)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 13, 2016
First Posted
July 20, 2016
Study Start
September 1, 2015
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
July 27, 2016
Record last verified: 2016-07